Table 2.
Characteristics and outcomes of severe/critical cases.
| Patient #1 | Patient #2 | Patient #3 | Patient #4 | |
|---|---|---|---|---|
| Age (Days) | 30 | 90 | 1 | 13 |
| Sex | Female | Male | Male | Female |
| Length of hospital stay | 15 days (all in ICU) | 75 days (all in ICU) | 75 days (18 days in ICU) | 70 days (47 in ICU) |
| Outcome | Death | Survive and discharge home | Survive and discharge home | Survive and discharge home |
| Lab | ||||
| RT-PCR for SARS-CoV-2 | 1st PCR +ve at presentation, 2nd PCR +ve (10 days later) | 1st PCR +ve at presentation, 2nd PCR –ve (29 days later) | 1st PCR +ve, 2nd PCR +ve (6 days late) | 1st PCR +ve, 2nd PCR –ve (4 days later) |
| Septic workup | Blood and urine CX negative, CSF not done | Blood and urine CX negative, CSF not done | Blood culture was negative, urine culture was positive (Klebsiella pneumonia), CSF not done | Blood and urine culture negative, CSF not done |
| White blood cell count x109/L | 11.3 (7.02–58.6) | 29.4 (5–29.4) | 5.99 (5.99–12.2) | 9 (3.57–32.7) |
| Neutrophil count x109/L | 2.71 (2.71–28.05) | 12.94 (2.16–22.4) | 0.6 (0.6–4.51) | 5.24 (0.56–11) |
| Lymphocyte count x109/L | 6.78 (1.12–16.41) | 10.29 (0.59–10.29) | 3.53 (3.37–9.18) | 2.29 (1.6–4.56) |
| Platelet count x109/L | 43 (29–427) | 221 (29–121) | 360 (201–575) | 242 (130–639) |
| Creatinine | 216 (max 249) | 79 (max 79) | 47 (max 81) | 71 (max 72) |
| Blood urea nitrogen | 23 (max 23) | 9.4 (max 9.4) | 1 (max 8.8) | 6.3 (max 7) |
| Sodium | 123 (min 123) | 139 (min 133) | 136 (min 135) | 147 (min 132) |
| Potassium | 6.4 (min 2.8) | 5.3 (min 2.7) | 5.1 (min 3.2) | 5.4 (min 3.5) |
| Lactate | 1.7 (max 8.2) | 3.2 | 2.7 (max 2.7) | 1.8 (max 7.74) |
| Alanine transaminase | 14 (max 74) | 1,070 (max 1,070) | NA (max 24) | 54 (max 54) |
| Aspartate transaminase | 73 (max 143) | 1,178 (max 1,178) | NA (max 36) | 152 (max 152) |
| Albumin | 31 (min 27) | 32 (min 17) | 32 (min 30) | 32 (min 25) |
| Lactate dehydrogenase | 1,580 (max 2,068) | 1,105 (max 1,105) | NA | NA |
| Creatine kinase-MB | 16.4 (max 16.4) | 40.6 (max 40.6) | NA (max NA) | NA (max 94) |
| Troponin | 684 (max 2,410) | 108 (max 1,294.2) | 46.3 (max 46.3) | NA (max 15,724.18) |
| Brain natriuretic peptide | 971 (max 1,127) | 1,370 (max 2,241) | 117.8 (max 390) | NA (max NA) |
| Partial thromboplastin time | 55.5 (max 118) | 38.1 (max 52.8) | 20.5 (max 61.8) | 53 (max 117) |
| International normalized ratio | 1.04 (max 1.55) | 1.49 (max 1.85) | 1.12 (max 3.37) | 1.16 (max 1.67) |
| D dimer | 5.5 (max 5.93) | 1.32 (max 1.85) | NA (max NA) | 5.89 (max 5.89) |
| fibrinogen | 2.25 (max 2.25) | 0.71 (max 0.55) | NA (max NA) | 1.3 (max 2) |
| C-reactive protein | 11 (max 22) | 56 (max 137) | 2 (max 2) | 3 (max 31) |
| Erythrocyte sedimentation rate | 2 (max 2) | 2 (max 2) | 2 (max 2) | 2 (max 84) |
| Procalcitonin | 1.7 (max 1.7) | 0.08 (?) | 0.09 (max 0.09) | 0.06 (max 0.06) |
| ferritin | 2,316 (max 6,130) | 813 (max 813) | NA (max NA) | NA (max NA) |
| Interleukin 6 | 9 | 9 | NA | NA |
| Tumor necrosis factor alpha | 19 | 26 | NA | NA |
| Chest x-ray | Bilateral opacities, pulmonary edema, atelectasis | Unilateral opacities, peribronchial thickening, pleural effusion | Pulmonary edema | Atelectasis |
| Echocardiography | Normal coronaries, small pericardial effusion EF mode 80.5 |
Mild TR, dilated RA, and RV, suprasystemic pulmonary hypertension, EF mode 60 |
Normal left ventricular systolic function, dilated left ventricle, large per membranous VSD |
TGA moderate VSD, moderate ASD II |
| Antibiotics | Total of 12 days | Total of 18 days | Total of 10 days | Total of 4 days |
| Respiratory support | CMV 12 days, HFO 2 days |
CMV 38 days, HFO 20 days, Bipap/CPAP 5 days |
Nasal canula 75 days | Bipap/CPAP 5 days |
| Duration of O2 support | 14 days | 72 days | 75 days | 15 days |
| Other medication | Hydralazine, amlodipine, anakinra, and heparin | Hydralazine, amlodipine, anakinra, sildenafil, aspirin, and enoxaparin | Captopril, furosemide | Captopril, propranolol, furosemide |
| IVIG | 2 doses (1 g/kg/dose) | 2 doses (1 g/kg/dose) | Not given | Not given |
| Steroid | Given | Given | Given | Not given |
| Antiviral | None | None | None | None |